ER(+), PR(−) breast cancers usually have higher levels of HER2 than ER(+), PR(+) tumors.[16] ER(+), PR(−) tumors overexpress HER2 in 21% of cases compared to 14% of ER(+), PR(+) tumors.[17]. Here, ERBB2 is linked to breast carcinoma.